Physician profile
Grace Chien
NPI 1164262143
$1,505.53
in general payments reported to CMS, 2019-2025
13 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $498 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.56 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $292.89 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $236.38 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $175.21 | 2024 | |
| Novo Nordisk INC | $106.68 | 2024-2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.60 | 2025 | Caplyta |
| Amgen INC. | $48.43 | 2025 | Repatha, Otezla |
| Exact Sciences Corporation | $44.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.97 | 2025 | Xifaxan |
| Dexcom, INC. | $20.68 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $19.10 | 2024 | |
| Abbott Laboratories | $17.29 | 2025 | Eterna |
| Glaxosmithkline, LLC. | $16.77 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.